Table 3.
Characteristics of intervention within treatment arms
| Trial | Both arms | AIMT arm | Medical care (IV rt-PA) arm | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No of patients* | No (%) IV rt-PA | No of patients* | No (%) receiving thrombectomy | No (%) receiving IV rt-PA | No (%) receiving IA rt-PA | No (%) receiving thrombectomy+IV rt-PA | No of patients* | No (%) of IV rt-PA | |||
| IMS III28 | 656 | 656 (100) | 434 | 170 (39.2) | 434 (100)† | 266 (61.3) | 170 (39.2) | 222 | 222 (100) | ||
| SYNTHESIS29 | 362 | 178 (49.2) | 181 | 56 (30.9) | 0 (0) | 109 (60.2) | 0 (0)/56 (30.9)‡ | 181 | 178 (98.3) | ||
| MR RESCUE30 | 127 | 44 (34.6) | 70 | 61 (87.1) | 28 (40.0) | 8 (11.4) | 28 (40.0) | 57 | 16 (28.1) | ||
| MR CLEAN31 | 500 | 445 (89.0) | 233 | 195 (83.7) | 203 (87.1) | 25 (10.7) | NS | 267 | 242 (90.6) | ||
| ESCAPE32 | 315 | 238 (75.6) | 165 | 151 (91.5) | 120 (72.7) | NA | 120 (72.7) | 150 | 118 (78.7) | ||
| EXTEND-IA33 | 70 | 70 (100) | 35 | 27 (77.1) | 35 (100) | NA | 27 (77.1) | 35 | 35 (100) | ||
| SWIFT PRIME34 | 191 | 191 (100) | 98§ | 87 (88.8)§ | 98 (100)§ | NA | 87 (88.8)‡ | 93‡ | 93 (100)§ | ||
| REVASCAT35 | 206 | 150 (72.8) | 103 | 98 (95.1) | 70 (68.0) | 1 (1.0) | NS | 103 | 80 (77.7) | ||
| THERAPY36 | 108 | 108 (100) | 55 | NS | 55 (100) | 0 (0.0) | NS | 53 | 53 (100) | ||
| THRACE37 | 385 | 385 (100) | 190 | NS | 190 (100) | 0 (0.0) | NS | 195 | 195 (100) | ||
AIMT=adjuvant intra-arterial mechanical thrombolysis; IV=intravenous; IA=intra-arterial; NA=not applicable; NS=not specified; rt-PA=recombinant tissue plasminogen activator.
*Intention to treat population.
†Approximately two thirds of standard dose.
‡IA rt-PA.
§Modified intention to treat population.